Thioredoxin induces Tregs to generate an immunotolerant tumor microenvironment in metastatic melanoma

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Oncoimmunology

• Publication date

  2015-05-27

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1080/2162402X.2015.1027471PMID 26405597PMCID PMC4570104
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• IL-2 therapy promotes suppressive ICOS+ Treg expansion in melanoma patients.

  2014cited by this paper
• Antioxidants Accelerate Lung Cancer Progression in Mice

  2014cited by this paper
• Oxidants, antioxidants and the current incurability of metastatic cancers

  2013cited by this paper
• FOXP3 regulates sensitivity of cancer cells to irradiation by transcriptional repression of BRCA1.

  2013cited by this paper
• Regulatory T cells in nonlymphoid tissues

  2013cited by this paper
• The Thioredoxin System as a Therapeutic Target in Human Health and Disease

  2013cited by this paper
• Restoring Immune Function of Tumor-Specific CD4+ T Cells during Recurrence of Melanoma

  2013cited by this paper
• Thioredoxin and Thioredoxin Target Proteins: From Molecular Mechanisms to Functional Significance

  2013cited by this paper
• The Tumor Microenvironment: Characterization, Redox Considerations, and Novel Approaches for Reactive Oxygen Species-Targeted Gene Therapy

  2013cited by this paper
• Melanoma: from mutations to medicine.

  2012cited by this paper
• Melanoma-induced immunosuppression and its neutralization.

  2012cited by this paper
• Regulatory T cells in melanoma: the final hurdle towards effective immunotherapy?

  2012cited by this paper
• T-regulatory cells: key players in tumor immune escape and angiogenesis.

  2012cited by this paper
• Immunotherapy for malignant melanoma.

  2012cited by this paper
• Immunotherapy for Malignant Melanoma Robert

  2012cited by this paper
• Changes in Peripheral Blood Level of Regulatory T cells in Patients with Malignant Melanoma During Treatment with Dendritic Cell Vaccination and Low‐dose IL‐2

  2011cited by this paper
• Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells

  2011cited by this paper
• A CCR4 antagonist combined with vaccines induces antigen-specific CD8+ T cells and tumor immunity against self antigens.

  2011cited by this paper
• Measurement of reactive oxygen species in the culture media using Acridan Lumigen PS-3 assay.

  2011cited by this paper
• Phenotypical and functional specialization of FOXP3+ regulatory T cells

  2011cited by this paper
• CXCL12/CXCR4 blockade induces multimodal antitumor effects that prolong survival in an immunocompetent mouse model of ovarian cancer.

  2011cited by this paper
• Regulatory T cells in tumor immunity

  2010cited by this paper
• Regulatory T-Cell–Mediated Attenuation of T-Cell Responses to the NY-ESO-1 ISCOMATRIX Vaccine in Patients with Advanced Malignant Melanoma

  2009cited by this paper
• Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma

  2008cited by this paper
• TGF-β and Regulatory T Cell in Immunity and Autoimmunity

  2008cited by this paper
• Thioredoxin signaling as a target for cancer therapy.

  2007cited by this paper
• Administration of a CD25-Directed Immunotoxin, LMB-2, to Patients with Metastatic Melanoma Induces a Selective Partial Reduction in Regulatory T Cells In Vivo1

  2007cited by this paper
• Thioredoxin-1 modulates transcription of cyclooxygenase-2 via hypoxia-inducible factor-1alpha in non-small cell lung cancer.

  2006cited by this paper
• Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma.

  2006cited by this paper
• High Thioredoxin Expression Is Associated with Resistance to Docetaxel in Primary Breast Cancer

  2005cited by this paper
• The thioredoxin-thioredoxin reductase system: over-expression in human cancer.

  2003influential reference
• Increased expression of thioredoxin-1 in human colorectal cancer is associated with decreased patient survival.

  2003cited by this paper
• Thioredoxin expression is associated with lymph node status and prognosis in early operable non-small cell lung cancer.

  2001cited by this paper
• Immunotherapy of malignant melanoma.

  1982cited by this paper

• Inhibition of Thioredoxin-Reductase by Auranofin as a Pro-Oxidant Anticancer Strategy for Glioblastoma: In Vitro and In Vivo Studies

  2025cites this paper
• Exploring the Role of Thioredoxin system in Cancer Immunotherapy

  2025cites this paper
• Thioredoxin (Trx): A redox target and modulator of cellular senescence and aging-related diseases

  2024cites this paper
• Current Insights into the Role of UV Radiation-Induced Oxidative Stress in Melanoma Pathogenesis

  2024cites this paper
• Facts, Dogmas, and Unknowns About Mitochondrial Reactive Oxygen Species in Cancer

  2024cites this paper
• Melanoma redox biology and the emergence of drug resistance.

  2024cites this paper
• A metabolic perspective on nitric oxide function in melanoma.

  2023cites this paper
• NRF2 and Key Transcriptional Targets in Melanoma Redox Manipulation

  2022cites this paper
• Redox-Related Proteins in Melanoma Progression

  2022cites this paper
• Oxidative Stress-Related Mechanisms in Melanoma and in the Acquired Resistance to Targeted Therapies

  2021cites this paper
• Common clonal origin of conventional T cells and induced regulatory T cells in breast cancer patients

  2021cites this paper
• Perspective on the treatment of non-small cell lung cancer in the context of potential SARS-CoV-2 infection during the pandemic.

  2021cites this paper
• Cisplatin Resistance and Redox-Metabolic Vulnerability: A Second Alteration

  2021cites this paper
• Comparative transcriptome profiling of horseshoe crab Tachypleus gigas hemocytes in response to lipopolysaccharides.

  2021cites this paper
• Thioredoxin Reductase Inhibition for Cancer Therapy.

  2021cites this paper
• Patients with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Greatly Improved Fatigue Symptoms When Treated with Oxygen-Ozone Autohemotherapy

  2021cites this paper
• Male vs. Female Differences in Responding to Oxygen–Ozone Autohemotherapy (O2-O3-AHT) in Patients with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)

  2021cites this paper
• Oxidative Stress-Inducing Anticancer Therapies: Taking a Closer Look at Their Immunomodulating Effects

  2020cites this paper
• Cyclophosphamide with or without fluorouracil followed by subcutaneous or intravenous interleukin‐2 use in solid tumors: A feasibility off‐label experience

  2019cites this paper
• Role of Reactive Oxygen Species and Targeted Therapy in Metastatic Melanoma

  2018cites this paper
• Inhibiting TrxR suppresses liver cancer by inducing apoptosis and eliciting potent antitumor immunity

  2018cites this paper
• IL-4Rα aptamer-liposome-CpG oligodeoxynucleotides suppress tumour growth by targeting the tumour microenvironment

  2017cites this paper
• Ccl22 Diverts T Regulatory Cells and Controls the Growth of Melanoma.

  2016cites this paper